Circulating vaccine-derived poliovirus type 1 confirmed in Papua New Guinea

Outbreak response to be launched to stop further spread of the virus

A child is protected from lifelong polio paralysis through OPV vaccination. © WHO
A child is protected from lifelong polio paralysis through OPV vaccination. © WHO

Following identification last month of an acute flaccid paralysis (AFP) case from which vaccine-derived poliovirus type 1 (VDPV1) had been isolated, genetic sequencing of two VDPV1s from two non-household contacts of the AFP case has now confirmed that VDPV1 is circulating and is being officially classified as a  ‘circulating’ VDPV type 1 (cVDPV1).

The National Department of Health (NDOH) of Papua New Guinea is closely working with the GPEI partners in launching a comprehensive response. Some of the immediate steps include conducting large-scale immunization campaigns and strengthening surveillance systems that help detect the virus early. These activities are also being strengthened in neighboring provinces.

The GPEI and its partners are continuing to work with regional and country counterparts and partners in supporting the Government of Papua New Guinea and local public health authorities in conducting a full field investigation, risk assessment and to support the planning, implementation and monitoring of the outbreak response.

For more information:

Contact Oliver Rosenbauer, Communications Officer, Global Polio Eradication Initiative, tel: +41 79 500 6536

Related resources


Related News

   07/08/2024
7 August 2024
   30/07/2024
Athletes from around the world unite for a polio-free future
   19/07/2024
Circulating variant type 2 poliovirus (cVDPV) has been confirmed in the Gaza Strip. Virus was isolated from six environmental (sewage) samples, collected from two different collection sites in two sub-regions within Gaza, collected on 23 June 2024.
   12/06/2024
Our sincerest condolences for the loss
   06/06/2024
Advocating for a Polio-Free Future for Every Child